OBJECTIVES: CMS’ mandatory bundle for hip and knee arthroplasty necessitates provider accountability for quality and cost of care to 90-days. Wound closure is a key area to consider within hip and knee arthroplasty. The DERMABOND® PRINEO® Skin Closure System combines a topical skin adhesive with a self-adhering mesh without the need for dressing changes or suture or staple removal. This study estimated the budget impact of DERMABOND PRINEO System compared to other wound closure methods for hip and knee arthroplasty. METHODS:  A 90-day economic model was developed assuming 500 annual hip/knee arthroplasties for a typical U.S. hospital setting. In current practice, wound closure methods for the final skin layer was set to 50% sutures and 50% staples. In future practice, this distribution shifted to 20% sutures, 20% staples, and 60% DERMABOND PRINEO System. Healthcare resources included materials (eg, staplers, steri-strips, and traditional/barbed sutures), standard or premium dressings, outpatient visits, and home care visits. An Expert Panel, comprised of 3 orthopedic physician assistants, two orthopedic surgeons, and a home health representative, was used to inform several model parameters. Other inputs were informed by national data or literature. Unit costs were based on list prices in 2016 USD. RESULTS: The analysis predicted that use of DERMABOND PRINEO System could achieve cost savings of $56.70 to $79.62 per patient, when standard or premium wound dressings are used, respectively, with sutures or staples. This translated to an annual hospital budgetary savings ranging from $28,349 to $39,809 when assuming 500 arthroplasties. Dressing materials and post-operative healthcare visits were key drivers of the results. CONCLUSIONS: Based on the results of this analysis, it is anticipated that the DERMABOND PRINEO System may provide cost savings within hip and knee arthroplasties due to decreases in resource utilization in the post-acute care setting.